Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Nalorex

Small molecule · Antagonist

Phase 1 Most advanced trial (none active)
1 Registered trials

What is Nalorex?

Nalorex is a drug administered to antagonize potential opioid effects from buprenorphine. It is studied in opioid-use disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Mechanism
Antagonist
Therapy area
Psychiatry
In trials of
INDV
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03715634 Phase 1 Opioid-use Disorder Completed INDV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Opioid-use Disorder

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.